Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug 15;391(7):662-664.
doi: 10.1056/NEJMc2408029.

T-Cell Neoplasms after B-Cell Neoplasms - The Pre-CAR T-Cell Era

Graça M Dores  1 , Lindsay M Morton  1
Affiliations
Comment

T-Cell Neoplasms after B-Cell Neoplasms - The Pre-CAR T-Cell Era

Graça M Dores et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Observed and expected IRs and corresponding SIRs for T-cell lymphoma/leukemia after all B-cell lymphoma/leukemia combined, by T-cell lymphoma/leukemia subtype, age at B- cell lymphoma/leukemia diagnosis, and time since B-cell lymphoma/leukemia diagnosis (A), and for all T-cell lymphoma/leukemia combined after B-cell lymphoma/leukemia, by B-cell lymphoma/leukemia subtype, age at B-cell lymphoma/leukemia diagnosis, and time since B-cell lymphoma/leukemia diagnosis (B), 2000–2016 (follow-up through 2017)*
* T-cell lymphoma/leukemia IRs after B-cell lymphoma/leukemia and SIRs were not calculated when there were <3 observed cases. Wide confidence bounds emphasize the instability of incidence rate estimates based on small numbers of cases after B-cell lymphoma/leukemia. Data (released April 2023, based on the November 2022 submission) were derived from the MP-SIR session of SEER*Stat software (version 8.4.3) and are available at www.seer.cancer.gov/seerstat. Abbreviations: precursor acute lymphoblastic leukemia/lymphoma (ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), mycosis fungoides/Sézary syndrome (MF/SS), peripheral T-cell lymphoma (PTCL), 17 cancer registry areas of the Surveillance, Epidemiology, and End Results Program (SEER-17). formula image IR, B-cell lymphoma/leukemia patients, <1 year formula image IR, B-cell lymphoma/leukemia patients, ≥1 year formula image IR, General population, <1 year formula image IR, General population, ≥1 year formula image SIR, <1 year formula image SIR, ≥1 year
Figure 1.
Figure 1.. Observed and expected IRs and corresponding SIRs for T-cell lymphoma/leukemia after all B-cell lymphoma/leukemia combined, by T-cell lymphoma/leukemia subtype, age at B- cell lymphoma/leukemia diagnosis, and time since B-cell lymphoma/leukemia diagnosis (A), and for all T-cell lymphoma/leukemia combined after B-cell lymphoma/leukemia, by B-cell lymphoma/leukemia subtype, age at B-cell lymphoma/leukemia diagnosis, and time since B-cell lymphoma/leukemia diagnosis (B), 2000–2016 (follow-up through 2017)*
* T-cell lymphoma/leukemia IRs after B-cell lymphoma/leukemia and SIRs were not calculated when there were <3 observed cases. Wide confidence bounds emphasize the instability of incidence rate estimates based on small numbers of cases after B-cell lymphoma/leukemia. Data (released April 2023, based on the November 2022 submission) were derived from the MP-SIR session of SEER*Stat software (version 8.4.3) and are available at www.seer.cancer.gov/seerstat. Abbreviations: precursor acute lymphoblastic leukemia/lymphoma (ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), mycosis fungoides/Sézary syndrome (MF/SS), peripheral T-cell lymphoma (PTCL), 17 cancer registry areas of the Surveillance, Epidemiology, and End Results Program (SEER-17). formula image IR, B-cell lymphoma/leukemia patients, <1 year formula image IR, B-cell lymphoma/leukemia patients, ≥1 year formula image IR, General population, <1 year formula image IR, General population, ≥1 year formula image SIR, <1 year formula image SIR, ≥1 year
See this image and copyright information in PMC

Comment on

References

    1. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023;20(6):359–371. DOI: 10.1038/s41571-023-00754-1. - DOI - PMC - PubMed
    1. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med 2024;390(7):584–586. DOI: 10.1056/NEJMp2400209. - DOI - PubMed
    1. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28(33):4935–44. (In eng). DOI: 10.1200/JCO.2010.29.1112. - DOI - PMC - PubMed
    1. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 2015;373(26):2499–511. DOI: 10.1056/NEJMoa1505949. - DOI - PubMed
    1. Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 2021;138(9):785–789. (Article) (In English). DOI: 10.1182/blood.2020010497. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources